07:00 , Jul 21, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Hematology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Hematology Anemia Hemochromatosis type 2 juvenile (HFE2); hepcidin A study in rats suggests a soluble form of HFE2 may help treat anemia of chronic disease. In...
08:00 , Nov 22, 2010 |  BC Week In Review  |  Company News

Isis, Xenon deal

Xenon partnered with Isis to discover and develop antisense therapeutics to treat anemia of inflammation. Isis will discover candidates against hemochromatosis type 2 juvenile (HFE2) and hepcidin antimicrobial peptide (HAMP) . Isis will receive an...
01:31 , Nov 17, 2010 |  BC Extra  |  Company News

Isis, Xenon in antisense deal

Xenon Pharmaceuticals Inc. (Burnaby, B.C.) partnered with Isis Pharmaceuticals Inc. (NASDAQ:ISIS) to discover and develop antisense therapeutics to treat anemia of inflammation. Isis will discover candidates against hemochromatosis type 2 juvenile (HFE2) and hepcidin antimicrobial...
08:00 , Mar 5, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Hematology

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Hematology Anemia; hemochromatosis Bone morphogenetic protein 6 (BMP6); hemochromatosis (HFE); hemochromatosis type 2 (juvenile) (HFE2); hepcidin antimicrobial peptide (HAMP) Two separate...